Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1995-3-23
|
pubmed:abstractText |
Thirty-five patients (pts.) with advanced renal cell carcinoma were treated with a combination of vinblastine (5 mg/m2/IV) plus epirubicin (50 mg/m2/IV) every 3-4 weeks, alpha-2-A-interferon (9 x 10(6) U/IM 3 times in the 1st week, then 18 x 10(6) U/IM 3 times weekly), and medroxyprogesterone acetate (2,000 mg/os/day plus 500 mg IM/week). Thirty-one patients were males and 4 were females with a median age of 63 years (range 35-75) and median performance status of 70% (range 50-90%). We observed nine partial remissions (26%) with median duration of 40 weeks (range 20-232+). Fifteen pts. had no change (43%) while 11 pts. progressed (31%). The main side-effects were: leukopenia (29/35, 83%) with median nadir of 3,100 WBC/mm3 (range 510-3,990) and fever (32/35, 91%). Thrombocytopenia occurred in 4 pts. (11%), anemia in 5 (14%), asthenia in 12 (34%), nausea/vomiting in 12 (34%), alopecia in 8 (23%) and stomatitis in 3 (8.5%). Two patients stopped the therapy with medroxyprogesterone acetate because of muscular cramps. Median survival was 65 weeks (range 6-327+). We conclude that the combination of recombinant alpha 2A-interferon-vinblastine-epirubicin and medroxyprogesterone acetate has modest but definitive activity in patients with advanced renal cell carcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Medroxyprogesterone Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1120-009X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
6
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
349-53
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7861200-Adult,
pubmed-meshheading:7861200-Aged,
pubmed-meshheading:7861200-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7861200-Carcinoma, Renal Cell,
pubmed-meshheading:7861200-Epirubicin,
pubmed-meshheading:7861200-Female,
pubmed-meshheading:7861200-Humans,
pubmed-meshheading:7861200-Interferon-alpha,
pubmed-meshheading:7861200-Kidney Neoplasms,
pubmed-meshheading:7861200-Male,
pubmed-meshheading:7861200-Medroxyprogesterone Acetate,
pubmed-meshheading:7861200-Middle Aged,
pubmed-meshheading:7861200-Recombinant Proteins,
pubmed-meshheading:7861200-Survival Rate,
pubmed-meshheading:7861200-Vinblastine
|
pubmed:year |
1994
|
pubmed:articleTitle |
Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma.
|
pubmed:affiliation |
Division of Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.
|
pubmed:publicationType |
Journal Article
|